BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Takashima Y, Kawaguchi A, Iwadate Y, Hondoh H, Fukai J, Kajiwara K, Hayano A, Yamanaka R. MicroRNA signature constituted of miR-30d, miR-93, and miR-181b is a promising prognostic marker in primary central nervous system lymphoma. PLoS One 2019;14:e0210400. [PMID: 30615673 DOI: 10.1371/journal.pone.0210400] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Sebestyén E, Nagy Á, Marosvári D, Rajnai H, Kajtár B, Deák B, Matolcsy A, Brandner S, Storhoff J, Chen N, Bagó AG, Bödör C, Reiniger L. Distinct miRNA Expression Signatures of Primary and Secondary Central Nervous System Lymphomas. The Journal of Molecular Diagnostics 2021. [DOI: 10.1016/j.jmoldx.2021.11.005] [Reference Citation Analysis]
2 Dvorská D, Škovierová H, Braný D, Halašová E, Danková Z. Liquid Biopsy as a Tool for Differentiation of Leiomyomas and Sarcomas of Corpus Uteri. Int J Mol Sci 2019;20:E3825. [PMID: 31387281 DOI: 10.3390/ijms20153825] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
3 Ashrafizadeh M, Najafi M, Mohammadinejad R, Farkhondeh T, Samarghandian S. Flaming the fight against cancer cells: the role of microRNA-93. Cancer Cell Int 2020;20:277. [PMID: 32612456 DOI: 10.1186/s12935-020-01349-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Nordmo C, Glehr G, Altenbuchinger M, Spang R, Ziepert M, Horn H, Staiger AM, Ott G, Schmitz N, Held G, Einsele H, Topp M, Rosenwald A, Rauert-Wunderlich H. Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma. Leuk Lymphoma 2021;62:1107-15. [PMID: 33353431 DOI: 10.1080/10428194.2020.1861268] [Reference Citation Analysis]
5 Zhou Q, Guo J, Huang W, Yu X, Xu C, Long X. Linc-ROR promotes the progression of breast cancer and decreases the sensitivity to rapamycin through miR-194-3p targeting MECP2. Mol Oncol 2020;14:2231-50. [PMID: 32335998 DOI: 10.1002/1878-0261.12700] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
6 Wang W, Wang J, Zhang J, Taq W, Zhang Z. miR‑222 induces apoptosis in human intervertebral disc nucleus pulposus cells by targeting Bcl‑2. Mol Med Rep 2019;20:4875-82. [PMID: 31638197 DOI: 10.3892/mmr.2019.10732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
7 Hübner M, Moellhoff N, Effinger D, Hinske CL, Hirschberger S, Wu T, Müller MB, Strauß G, Kreth FW, Kreth S. MicroRNA-93 acts as an "anti-inflammatory tumor suppressor" in glioblastoma. Neurooncol Adv 2020;2:vdaa047. [PMID: 32642700 DOI: 10.1093/noajnl/vdaa047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
8 Uzuner E, Ulu GT, Gürler SB, Baran Y. The Role of MiRNA in Cancer: Pathogenesis, Diagnosis, and Treatment. Methods Mol Biol 2022;2257:375-422. [PMID: 34432288 DOI: 10.1007/978-1-0716-1170-8_18] [Reference Citation Analysis]
9 Zajdel M, Rymkiewicz G, Sromek M, Cieslikowska M, Swoboda P, Kulinczak M, Goryca K, Bystydzienski Z, Blachnio K, Ostrowska B, Borysiuk A, Druzd-Sitek A, Walewski J, Chechlinska M, Siwicki JK. Tumor and Cerebrospinal Fluid microRNAs in Primary Central Nervous System Lymphomas. Cancers (Basel) 2019;11:E1647. [PMID: 31731456 DOI: 10.3390/cancers11111647] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
10 Takashima Y, Kawaguchi A, Fukai J, Iwadate Y, Kajiwara K, Hondoh H, Yamanaka R. Survival prediction based on the gene expression associated with cancer morphology and microenvironment in primary central nervous system lymphoma. PLoS One 2021;16:e0251272. [PMID: 34166375 DOI: 10.1371/journal.pone.0251272] [Reference Citation Analysis]
11 Skrzypek K, Nieszporek A, Badyra B, Lasota M, Majka M. Enhancement of myogenic differentiation and inhibition of rhabdomyosarcoma progression by miR-28-3p and miR-193a-5p regulated by SNAIL. Mol Ther Nucleic Acids 2021;24:888-904. [PMID: 34094709 DOI: 10.1016/j.omtn.2021.04.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Takashima Y, Kawaguchi A, Hayano A, Yamanaka R. CD276 and the gene signature composed of GATA3 and LGALS3 enable prognosis prediction of glioblastoma multiforme. PLoS One 2019;14:e0216825. [PMID: 31075138 DOI: 10.1371/journal.pone.0216825] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
13 Takashima Y, Kawaguchi A, Iwadate Y, Hondoh H, Fukai J, Kajiwara K, Hayano A, Yamanaka R. miR-101, miR-548b, miR-554, and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma. PLoS One 2020;15:e0229577. [PMID: 32101576 DOI: 10.1371/journal.pone.0229577] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
14 Takashima Y, Kawaguchi A, Yamanaka R. Promising Prognosis Marker Candidates on the Status of Epithelial-Mesenchymal Transition and Glioma Stem Cells in Glioblastoma. Cells 2019;8:E1312. [PMID: 31653034 DOI: 10.3390/cells8111312] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
15 Takashima Y, Hamano M, Fukai J, Iwadate Y, Kajiwara K, Kobayashi T, Hondoh H, Yamanaka R. GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL. Sci Rep 2020;10:8435. [PMID: 32439996 DOI: 10.1038/s41598-020-65463-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]